与帕唑帕尼相关的伴有后部可逆性脑病综合征的子宫肉瘤。
Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
机构信息
Department of Pharmacy, Kagawa University Hospital, Kagawa, Japan.
Emergency Medical Centre, Kagawa University Hospital, Kagawa, Japan.
出版信息
J Clin Pharm Ther. 2021 Feb;46(1):223-226. doi: 10.1111/jcpt.13261. Epub 2020 Oct 12.
WHAT IS KNOWN AND OBJECTIVE
Our objective is to report on a case of posterior reversible encephalopathy syndrome associated with pazopanib.
CASE DESCRIPTION
A 64-year-old patient with uterine sarcoma developed PRES 3 days after pazopanib was initiated. After the discontinuation of pazopanib, the symptoms of PRES improved.
WHAT IS NEW AND CONCLUSION
The first report worldwide to describe a patient with uterine sarcoma experiencing PRES caused by pazopanib. Patients with uterine sarcoma may experience PRES, even in the early phase of pazopanib therapy.
已知和目的
我们的目的是报告一例与帕唑帕尼相关的后部可逆性脑病综合征。
病例描述
一名 64 岁的子宫肉瘤患者在开始使用帕唑帕尼后 3 天出现 PRES。停止使用帕唑帕尼后，PRES 的症状有所改善。
新发现和结论
这是全球首例报告的子宫肉瘤患者因帕唑帕尼引起 PRES 的病例。子宫肉瘤患者可能会出现 PRES，即使在帕唑帕尼治疗的早期阶段也是如此。
Zotero 插件